stockrow
Friday 6 November 2026
Export ELVN’s income statement to Excel — free account
Enliven Therapeutics, Inc.
ELVN Healthcare Biotechnology
- EPS
- 0.00%
- Free cash flow
- −8.34%
Quarter to June 2026, against a year earlier
48.65
3.86
+8.62%
Follow ELVN
Alert me
Enliven Therapeutics, Inc. (ELVN) EBITDA
Enliven Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$119.6M, compared with −$103.8M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$123.8M. Over the past ten years it has ranged from −$119.6M (fiscal 2025) to −$24.1M (fiscal 2019) — the current reading is the lowest in ten years. EBITDA has fallen for 3 consecutive fiscal years. Enliven Therapeutics, Inc. ranks 450th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$119.6M | — |
| FY2024 | −$103.8M | — |
| FY2023 | −$87.8M | — |
| FY2022 | −$38.6M | — |
| FY2021 | −$51.2M | — |
| FY2020 | −$41.5M | — |
| FY2019 | −$24.1M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$36.7M | — |
| Mar 2026 | −$27.5M | — |
| Dec 2025 | −$34.2M | — |
| Sep 2025 | −$25.3M | — |
| 26 more quarters | Free account |
Against its own ten years
Low −$119.6M
High −$24.1M
Ten-year median
−$51.2M
Current reading's percentile
14
EBITDA against peers
| Company | EBITDA |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $96.1M |
| ELVN Enliven Therapeutics, Inc. | −$123.8M |
| CELC Celcuity, Inc. compare | −$204.0M |
| VRDN Viridian Therapeutics, Inc. compare | −$474.6M |
| DNLI Denali Therapeutics Inc. compare | −$524.5M |
| DYN Dyne Therapeutics, Inc. compare | −$536.1M |
| VKTX Viking Therapeutics, Inc. compare | −$652.8M |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$695.5M |
| TLX Telix Pharmaceuticals Limited compare | — |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item